Bivalirudin: A review of its potential place in the management of acute coronary syndromes

Drugs

Volumn 62, Issue 5, 2002, Pages 841-870

  Carswell, Christopher I ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOPEPTIDE A; HIRULOG;

AGE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; META ANALYSIS; NONHUMAN; PHARMACODYNAMICS; REVIEW; STENT; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0036247598     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262050-00008     Document Type: Review

References (99)

1. New anticoagulant drugs
2. Novel antithrombotic drugs in development
3. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
4. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery
5. Thrombin functions and antithrombotic intervention
6. Thrombin and antithrombotics
7. The coagulation cascade: Initiation, maintenance, and regulation
8. The human pharmacology of thrombin inhibition
9. Role of thrombin signalling in platelets in haemostasis and thrombosis
10. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease
11. Optimizing anticoagulant and antiplatelet therapy for interventional cardiology procedures: Where do we stand in 1998?
12. Kinetic mechanism for the interaction of hirulog with thrombin
13. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin
14. Prevention of activation of blood coagulation during acute coronary ischemic syndromes: Beyond aspirin and heparin
15. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin
16. Transcellular signaling and pharmacological modulation of thrombin- induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells
17. Inhibition by Hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin
18. Human umbilical vein smooth muscle cells as a model to study thrombin generation and function: Effect of thrombin inhibitors
19. Direct inhibition of protein Ca by site directed thrombin inhibitors: Implications in anticoagulant and thrombolytic therapy
20. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery
21. Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury
22. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model
23. Antithrombotic effects of hirulog in a rat carotid endarterectomy model
24. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model
25. Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model
26. Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting
27. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans
28. Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
29. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
30. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
31. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
32. The HERO-2 Trial
33. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
34. Initial experience with a direct antithrombin, Hirulog, in unstable angina: Anticoagulant, antithrombotic, and clinical effects
35. Direct thrombin inhibition by bivalirudin combined with abciximab, a GP IIb/IIIa antagonist, during percutaneous coronary intervention: Favorable hemostatic profile compared to heparin/abciximab
36. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD)
37. The use of bivalirudin in patients with renal impairment
38. Dosage, pharmacological effects and clinical outcomes for bivalirudin in pereutaneous coronary intervention
39. Bivalirudin: A new generation antithrombotic drug
40. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
41. Potential interaction of bivalirudin and heparin after interchange of these agents
42. ACC/AHA guidelines for percutaneous coronary intervention (Revision of the 1993 PTCA Guidelines)-executive summary
43. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina
44. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions
45. Bivalirudin (Hirulog) reduces ischaemic rebound in comparison to heparin after coronary angioplasty
46. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty
47. Switching from heparin to a thrombin-specific anticoagulant (bivalirudin) for PTCA in unstable angina patients reduces major clinical events
48. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
49. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results
50. Antithrombin, antiplatelet therapy or both during PCI: A preliminary randomized trial
51. Bivalirudin during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia: Interim results of the ATBAT Trial
52. Bivalirudin for percutaneous coronary interventions: Development perspective
53. Effect of direct thrombin inhibition with bivalirudin (Hirulog) on restenosis after coronary angioplasty
54. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial
55. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial
56. Clinical outcomes of bivalirudin for ischemic heart disease
57. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials
58. Bivalirudin (Angiomax) for angioplasty
59. Evaluation of the role of coronary angioplasty in patients with unstable angina pectoris
60. In-hospital costs of percutaneous coronary revascularization. Critical determinants and implications
61. Antithrombotic therapy in patients undergoing coronary angioplasty
62. Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty
63. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
64. A randomized trial of aspirin in PTCA: Effect of high vs low dose aspirin on major complications and restenosis
65. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up
66. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapuetic profile
67. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty
68. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial
69. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrillin to Minimise Platelet Aggregation and Coronary Thrombosis-II
70. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomised Efficacy Study of Tirofiban for Outcomes and Restenosis
71. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
72. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
73. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
74. A second look at bivalirudin
75. Cost analysis of bivalirudin in percutaneous coronary intervention
76. Percutaneous coronary intervention: Changing practice patterns and outcomes 1995-1997
77. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
78. Risk of myocardial infarction and death during treatment with low dose aspirin and intavenous heparin in men with unstable coronary artery disease
79. Aspirin, heparin, or both to treat acute unstable angina
80. Aspirin, sulfinpyrazone, or both in unstable angina
81. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
82. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
83. Reactivation of unstable angina after the discontinuation of heparin
84. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users; primary end points analysis from the ATACS trial
85. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
86. Unstable angina: Current concepts of pathogenesis and treatment
87. The ideal fibrinolytic: Can drug design improve clinical results?
88. A comparison of reteplase with alteplase for acute myocardial infarction
89. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
90. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics
91. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction
92. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
93. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
94. Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials